2022-501460-17-00招募中1 期
Live Attenuated Rift Valley Fever Vaccine for Single Shot Administration (LARISSA)
Cr2o B.V.1 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2022年7月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 75
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Bart Hendriks
Scientific
Cr2o B.V.
研究点 (1)
Loading locations...
相似试验
撤回
1 期
KISIMA-02 vaccine-based immunotherapy for patients with mutated pancreatic cancer2022-501854-12-00Amal Therapeutics S.A.15
已完成
不适用
Safety and efficacy of live attenuated vaccine in patients received hematopoietic stem cell transplantatioRecipients of hematopoietic stem cell transplantationJPRN-UMIN000016500Fukkuoka Blood and Marrow Transplantation Group300
已完成
不适用
The efficacy and safety of live attenuated vaccine in patients treated with steroid and immunosuppresive drugs: A prospective studycollagen diseases, kidney diseases, digestive diaseases, liver diaseases, neurological diseases, kidney transplant patientsJPRN-UMIN000018627Department of Pediatrics, Yokohama City University80
招募中
4 期
Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis2024-512881-32-00Justus-Liebig-Universitaet Giessen336
进行中（未招募）
1 期
Effictiveness and safety of vaccination with Live-attenuated Influenza VaccineEUCTR2015-003250-41-GBPublic Health England2,500